All In Biotech

Drug Trial Radar · NCT06667544

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

A Phase 1/2, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of RNK08954 in Patients With Advanced Solid Tumors With a KRAS G12D Mutation TRIAD1 (Trial of RNK08954 In KRAS G12D Mutation)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Nov 8, 2024

Primary completion

Dec 2026

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human (FIH), Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of RNK08954 to determine the optimal dose and recommended dose for expansion and evaluate clinical activity in patients with advanced solid tumors with KRAS G12D mutation. This is a 2-part study: dose exploration/indication expansion and dose optimization ( to identify a dose that preserves clinical benefit with optimal tolerability).

Conditions

  • KRAS G12D Mutation

Interventions

  • RNK08954-01Drug

    Once daily oral treatment for a 3 week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs).Time frame: 12-15 months
  2. Optimal Biological Dose (OBD).Time frame: 12-15 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.